A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis

Guo, Xinjian; Zhao, Fuxing; Ma, Xinfu; Shen, Guoshuang; Ren, Dengfeng; Zheng, Fangchao; Du, Feng; Wang, Ziyi; Ahmad, Raees; Yuan, Xinyue; Zhao, Junhui; Zhao, Jiuda

doi:10.1186/s12885-019-6294-9

Table 1 Characteristics of the subjects in eligible studies

From: A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis

Study	Number Arms	Efficacy				Age		Sex		Disease status				ECOG
		OS	PFS	TTP	ORR	Median	Range	Male		LA		ME		0-1		≥2
		Median months						N	%	N	%	N	%	N	%	N	%
Fluoropyrimidine-based
Ajani 2005	79 DTX+Cis+5-FU	9.6	5.9	NA	43	57	21-83	53	70	4	6	72	95	79	100	0	1
Ajani 2005	76 DTX+Cis	10.5	5	NA	26	57	30-76	61	77	1	1	75	95	75	99	0	1
Douglass 1984	46 5-FU+Doxo+MMC	29.5	NA	NA	39	61.0	32-81	35	76	0	0	46	100	30	65	16	35
Douglass 1984	46 Doxo+MMC	19	NA	NA	29	58	33-78	37	80	0	0	46	100	28	61	18	39
Roth 2007	41 DTX+Cis+5-FU	10.4	NA	4.6	36.6	61	35-78	30	73	2	5	39	95	41	100	0	0
Roth 2007	38 DTX+Cis	11.0	NA	3.6	18.4	58	40-70	29	76	7	18	31	82	38	100	0	0
Van Cutsem 2015	89 DTX+Ox+5-FU	14.6	7.6	NA	46.6	58	NA	61	69	0	0	89	100	87	98	2	2
Van Cutsem 2015	79 DTX+Ox	8.93	4.5	NA	23.1	59	NA	51	65	0	0	79	100	77	99	1	1
Platinum-based
Kikuchi K 1990	32 ADM+5-FU+Cis	NA	NA	NA	6	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Kikuchi K 1990	33 ADM+5-FU	NA	NA	NA	0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	N
Park 2008	45 Cis+Iri+5-FU	10.5	6.2	NA	42	52	29-70	30	76	0	0	45	100	38	84	7	16
Park 2008	46 Iri+5-FU	10.7	4.8	NA	42	55	26-73	30	67	0	0	45	100	35	78	11	29
Roth 1999	61 Epi+Cis+5-FU	9.6	NA	NA	42.6	54	NA	37	61	12	22	42	78	24	39	30	61
Roth 1999	61 Epi+5-FU	7.1	NA	NA	28.6	56	NA	42	69	16	30	40	84	27	44	29	56
Anthracyclin-based
Douglass 1984	39 5-FU+Doxo+Me	5.5	NA	NA	29	59.5	43-76	28	71	0	0	39	100	30	77	9	23
Douglass 1984	48 5-FU+Me	3.3	NA	NA	14	62.0	24-79	38	80	0	0	48	100	35	72	13	28
Kim 2001	48 Epi+Cis+5-FU	8.5	NA	4.4	41.5	55	NA	45	75	3	5	57	95	54	90	6	10
Kim 2001	48 Cis+5-FU	7.3	NA	3.9	37.7	56	NA	42	70	3	5	57	95	53	88	7	12
KRGCGC 1992	25 Epi+Cis+5-FU	6.9	NA	NA	27	55	NA	45	75	3	5	57	97	54	90	6	10
KRGCGC 1992	22 Cis+5-FU	4	NA	NA	24	55	NA	45	75	3	5	57	95	54	90	6	10
Yun 2010	44 Epi+Cis+Cap	NA	6.5	NA	37	55	37-51	28	64	NA	NA	NA	NA	40	91	1	9
Yun 2010	47 Cis+Cap	NA	6.4	NA	38	58	33-75	34	72	NA	NA	NA	NA	41	87	4	13
MMC-based
Cullinan 1985	51 5-FU+Doxo+MMC	NA	NA	NA	38.5	60	NA	39	76	20	39	31	61	32	63	19	37
Cullinan 1985	49 Doxo+5-FU	NA	NA	NA	27.7	63	NA	37	76	18	37	31	63	33	67	16	33
Koizumi 2004	33 5-DFUR+Cis+MMC	8.03	NA	NA	25	58	36-79	19	58	NA	NA	NA	NA	16	48	13	39
Koizumi 2004	29 5-DFUR+Cis	5.97	NA	NA	17.2	58	37-79	17	59	NA	NA	NA	NA	25	86	6	24
Taxane-based
AI-Batran 2013	79 DTX+Ox+5-FU	17.3	9.1	NA	48.6	69	65-81	51	71	22	31	50	69	67	93	5	7
AI-Batran 2013	76 Ox+5-FU	14.5	7.1	NA	28.17	70	65-82	45	63	22	32	49	68	65	92	6	9
Van Cutsem 2006	227 DTX+Cis+5-FU	9.2	NA	5.6	37	55	26-79	159	72	6	3	213	96	218	99	3	1
Van Cutsem 2006	230 Cis+5-FU	8.6	NA	3.7	25	55	25-76	158	71	6	3	217	97	211	99	3	1
Wang 2015	119 DTX+Cis+5-FU	10.2	7.2	NA	48.7	56.6	19-80	81	68.1	30	25.2	89	77.4	115	96.6	4	3.4
Wang 2015	115 Cis+5-FU	8.5	4.9	NA	33.9	55.5	33-74	88	76.5	26	22.6	89	74.8	108	93.9	7	6.1
Yamada 2018	370 S-1+Cis	15.3	6.5	NA	56	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Yamada 2018	371 S-1+Cis+DOC	14.2	7.4	NA	59.3	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Irinotecan-based
Guimbaud 2014	209 Epi+Cis+Cape	9.5	5.3	NA	39.2	61.4	28-84	154	74	36	17	173	83	169	81	36	17
Guimbaud 2014	207 5-FU+Iri	9.7	5.8	NA	37.8	61.4	29-80	155	75	31	15	176	85	173	84	27	13
Lin 2009	13 5-FU+Ox+PTX	NA	NA	NA	62.5	55	36-67	18	72	NA	NA	NA	NA	NA	NA	NA	NA
Lin 2009	12 5-FU+Iri	NA	NA	NA	33.3	55	36-67	18	72	NA	NA	NA	NA	NA	NA	NA	NA
Other
Kim 1993	110 5-FU+Doxo+MMC	6.84	3	NA	25	54	19-77	68	62	NA	NA	NA	NA	75	68	23	21
Kim 1993	112 Cis+5-FU	8.61	5.5	NA	51	51	20-68	71	63	NA	NA	NA	NA	83	74	20	18
Li 2011	50 PTX+Cis+5-FU	10.8	NA	NA	48	59	20-74	32	68	22	46	28	56	NA	NA	NA	NA
Li 2011	44 Ox+5-FU	9.9	NA	NA	45.5	58	20-75	31	70	17	41	27	61	NA	NA	NA	NA
Maiello 2011	36 Epi+Cis+Cap	NA	NA	NA	54.3	58	39-74	22	60	NA	NA	NA	NA	NA	NA	NA	NA
Maiello 2011	31 DTX+5-FU	NA	NA	NA	22.6	61	44-75	23	74	NA	NA	NA	NA	NA	NA	NA	NA
Roth 2007	40 Epi+Cis+5-FU	8.3	NA	4.9	25	59	32-71	30	75	7	17	33	83	40	100	0	0
Roth 2007	41 DTX+Cis+5-FU	10.4	NA	4.9	36.6	61	35-78	30	73	2	5	39	95	41	10	0	0
Thuss-Patience 2005	45 Epi+Cis+5-FU	9.7	NA	5.5	35.6	63	33-75	36	80	1	2	44	98	44	98	1	2
Thuss-Patience 2005	45 DTX+5-FU	9.5	NA	5.3	37.8	62	34-75	29	64	1	2	44	98	42	95	2	4
Van Hoefer 2000	133 5-FU+Doxo+MTX	6.7	3.3	NA	12	58	30-74	96	72	22	17	111	83	117	88	16	12
	134 Cis+5-FU	7.2	4.1	NA	20	57	24-74	91	68	21	16	113	84	114	85	20	15
	132 Eto+5-FU+LV	7.2	3.3	NA	9	59	25-74	90	68	22	17	110	83	120	92	12	9

OS Overall survival, PFS Progression-free survival, TTP Time to progression, ORR Objective response rate, LA Locally advanced, ME Metastatic disease, ECOGE Eastern Cooperative Oncology Group performance status, NA Not applicable, DTX Docetaxel, DOC Docetaxel, PTX Palictaxel,Ciscisplatin, 5- FU Fluorouracil, Cape Capcapecitabine, Cap Capcapecitabine, 5-DFUR Doxifluridine, Ox Oxaliplatin, Doxo Doxorubicin, Epi Epirubicin, Iri Irinotecan, MMC Mitomycin C, Eto Etoposide, Cis Cisplatin, ADM Adriamycin, Me Methyl-CCNU, S-1 Tegafur

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Cancer

Contact us